Fabien Zoulim is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis'.

Dr. Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM, and in different national and international committees. He is currently a Governing Board member of the European Association for the Study of the Liver (EASL). Dr Zoulim received the William Prusoff award of the International Society for Antiviral Research in recognition of his work in the field of HBV molecular biology and anti-HBV therapy. Furthermore, he has been the scientific coordinator of a European community-funded Network of Excellence, Virgil, on the management of antiviral drug resistance, and is currently involved in several European projects. Dr. Zoulim is a recognized expert in the field of antiviral therapy and drug resistance. He has published more than 260 articles in the field of viral hepatitis.

Professor Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a Ph.D. in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia, US.